Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
Inzidenz kutaner immunvermittelter unerwünschter Ereignisse und Outcomes unter Immun-Checkpoint-Inhibitor-Regimen: systematische Übersicht und Metaanalyse
Cancers · 13.01.2024 · 16 (2) · 340
DOI: 10.3390/cancers16020340 ↗Auf einen Blick
In 174 Studien variierte die Inzidenz kutaner immunvermittelter unerwünschter Ereignisse je nach Tumor und Regime. Höhere cirAE-Inzidenz war mit besseren Outcomes und mit Kombinationstherapien assoziiert.
Fragestellung
Wie häufig treten kutane immunvermittelte unerwünschte Ereignisse unter ICI-Regimen auf, und wie sind sie mit Outcomes assoziiert?
Methode
Systematische Übersicht und Metaanalyse publizierter Studien zu anti-PD-1/PD-L1- und anti-CTLA-4-ICIs allein oder in Kombination bei Melanom, Nierenzellkarzinom, NSCLC und Urothelkarzinom.
Ergebnisse
Rash, Pruritus und Vitiligo waren am häufigsten berichtet; Inzidenzen 16,7 %, 18,0 % und 6,6 %. Höhere cirAE-Inzidenz war mit Kombinationen und CTLA-4-Regimen assoziiert; Vitiligo-Inzidenz mit Gesamtüberleben (p = 0,0483).
Schlussfolgerung der Autor:innen
Die Analyse liefert Referenzinzidenzen für cirAEs und zeigt auf Studienebene eine Assoziation mit günstigeren Behandlungsergebnissen bei soliden Tumoren.
Kernaussagen
- 174 Studien; häufigste cirAEs: Rash, Pruritus, Vitiligo
- Höhere cirAE-Inzidenz bei Kombinationen und CTLA-4-Regimen
- Vitiligo war signifikant mit Gesamtüberleben assoziiert (p = 0,0483)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.01.2024. Verfasst von Nina B Curkovic und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Vanderbilt University, Nashville, TN 37232, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI, Susan and Luke Simons Directorship for Melanoma.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are used to treat many cancers, and cutaneous immune-related adverse events (cirAEs) are among the most frequently encountered toxic effects. Understanding the incidence and prognostic associations of cirAEs is of importance as their uses in different settings, combinations, and tumor types expand. To evaluate the incidence of cirAEs and their association with outcome measures across a variety of ICI regimens and cancers, we performed a systematic review and meta-analysis of published trials of anti–programmed death-1/ligand-1 (PD-1/PD-L1) and anti–cytotoxic T lymphocyte antigen-4 (CTLA-4) ICIs, both alone and in combination with chemotherapy, antiangiogenic agents, or other ICIs in patients with melanoma, renal cell carcinoma, non-small cell lung cancer, and urothelial carcinoma. Key findings of our study include variable cirAE incidence among tumors and ICI regimens, positive association with increased cirAE incidence and response rate, as well as significant association between increased vitiligo incidence and overall survival. Across 174 studies, rash, pruritis, and vitiligo were the most reported cirAEs, with incidences of 16.7%, 18.0%, and 6.6%, respectively. Higher incidence of cirAEs was associated with ICI combination regimens and with CTLA-4-containing regimens, particularly with higher doses of ipilimumab, as compared to PD-1/L1 monotherapies. Outcome measures including response rate and progression-free survival were positively correlated with incidence of cirAEs. The response rate and incidence of pruritis, vitiligo, and rash were associated with expected rises in incidence of 0.17% (p = 0.0238), 0.40% (p = 0.0010), and 0.18% (p = 0.0413), respectively. Overall survival was positively correlated with the incidence of pruritis, vitiligo, and rash; this association was significant for vitiligo (p = 0.0483). Our analysis provides benchmark incidence rates for cirAEs and links cirAEs with favorable treatment outcomes at a study level across diverse solid tumors and multiple ICI regimens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Vanderbilt University, Nashville, TN 37232, USA.
- Vanderbilt Ingram Cancer Center, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Vanderbilt Ingram Cancer Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
ORCID-Profile: Nina B Curkovic
Förderung
- NCI NIH HHS
- NCI
- Susan and Luke Simons Directorship for Melanoma
- James C. Bradford Melanoma Fund
- Van Stephenson Melanoma Fund
Zitieren
APA
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024). Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis. Cancers, 16(2), 340. https://doi.org/10.3390/cancers16020340
Vancouver
Curkovic NB, Bai K, Ye F, Johnson DB. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis. Cancers. 2024;16(2):340. doi:10.3390/cancers16020340
BibTeX
@article{Curkovic2024,
author = {Curkovic, Nina B and Bai, Kun and Ye, Fei and Johnson, Douglas B},
title = {Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis},
journal = {Cancers},
year = {2024},
volume = {16},
number = {2},
pages = {340},
doi = {10.3390/cancers16020340}
}
EUVIMED